Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection.

Nature medicine·2026
Same author

Influenza coinfection inhibits control of mycobacterial infection in a human challenge model.

Nature communications·2026
Same author

Predicting trajectories of illness using RNA velocity of whole blood.

Nature communications·2026
Same author

VizCOM: A Novel Tool for Advanced Visualization and Analysis of Cardiac Optical Mapping Data.

Computing in cardiology·2026
Same author

Molecular epidemiology and clinical differentiation between <i>Clostridioides difficile</i> infection and colonization across three chicago medical centers.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026
Same author

Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18-49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

How stable are antimicrobial susceptibility profiles in serial clinical isolates? A retrospective study informing repeat-testing strategies.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Impact of low-dose chest CT and multiplex PCR on antibiotic usage for community-acquired pneumonia: multicentre prospective controlled before-after study with cluster randomisation (CAP-NEXT study).

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Clinical Microbiology and Infection: how did we do in 2025?

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Automate the work, not the decision: aligning expectations for AI in clinical microbiology.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Doxycycline prophylaxis and gonococcal resistance: reassurance, residual signals, and the case for surveillance.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Oral metronidazole versus clindamycin to treat bacterial vaginosis in pregnancies at risk for preterm labor.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2025

Development of a Larval Zebrafish Infection Model for Clostridioides difficile
09:13

Development of a Larval Zebrafish Infection Model for Clostridioides difficile

Published on: February 14, 2020

6.3K

How to develop a controlled human infection model for Clostridioides difficile.

Annefleur D O Hensen1, Maria J G T Vehreschild2, Dale N Gerding3

  • 1Leiden University Center for Infectious Diseases (LUCID), Leiden University Medical Center (LUMC), Leiden, The Netherlands.

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|August 30, 2024
PubMed
Summary
This summary is machine-generated.

Developing a controlled human infection model for Clostridioides difficile (C. difficile) is crucial for testing new treatments. Experts discussed challenges in creating a safe and effective model to combat C. difficile infection (CDI).

Keywords:
C. difficileCHIMClostridioides difficileControlled humanExpert opinionHuman challenge studyInfection

More Related Videos

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.5K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

38.7K

Related Experiment Videos

Last Updated: Jun 14, 2025

Development of a Larval Zebrafish Infection Model for Clostridioides difficile
09:13

Development of a Larval Zebrafish Infection Model for Clostridioides difficile

Published on: February 14, 2020

6.3K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.5K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

38.7K

Area of Science:

  • Microbiology
  • Immunology
  • Infectious Diseases

Background:

  • Clostridioides difficile (C. difficile) infection (CDI) is a major cause of hospital-acquired diarrhea with high relapse rates.
  • Antibiotic resistance and unknown factors in fecal microbiota transplantation (FMT) hinder effective treatment.
  • Novel non-antibiotic strategies are needed to enhance colonization resistance and immune responses against CDI.

Purpose of the Study:

  • To establish a framework for a Controlled Human Infection Model (CHIM) for toxigenic C. difficile.
  • To enable testing of novel therapeutic approaches and identification of microbiota/immunological targets for CDI.
  • To address the ethical, scientific, logistical, and biosafety challenges associated with a toxigenic C. difficile CHIM.

Main Methods:

  • International experts convened in a workshop organized by Inno4Vac to discuss challenges in developing a C. difficile CHIM.
  • Key challenges identified include creating a clinically relevant model with mild-to-moderate symptoms, determining optimal inoculum dose, and understanding antibiotic pre-treatment protocols.

Main Results:

  • The expert consensus highlighted the need to overcome specific challenges to enable a functional C. difficile CHIM.
  • The model aims to induce mild to moderate CDI symptoms, not severe disease.
  • Optimal C. difficile inoculum dose and antibiotic pre-treatment parameters are critical for model development.

Conclusions:

  • A successfully developed C. difficile CHIM will facilitate the evaluation of new anti-CDI products.
  • This model will provide a platform for deeper understanding of CDI pathophysiology, pathogenesis, and immunology.
  • The CHIM framework is essential for advancing research and developing effective interventions against C. difficile.